Predicting master transcription factors from pan-cancer expression data

Jessica Reddy(Cedars-Sinai Medical Center), Marcos A. Fonseca(Cedars-Sinai Medical Center), Rosario I. Corona(Cedars-Sinai Medical Center), Robbin Nameki(Cedars-Sinai Medical Center), Felipe Segato Dezem(Cedars-Sinai Medical Center), Isaac A. Klein(Dana-Farber Cancer Institute), Heidi Chang(Cedars-Sinai Medical Center), Daniele Chaves‐Moreira(Penn Center for AIDS Research), Lena K. Afeyan(Whitehead Institute for Biomedical Research), Tathiane M. Malta(Henry Ford Hospital), Xianzhi Lin(Cedars-Sinai Medical Center), Forough Abbasi(Cedars-Sinai Medical Center), Alba Font‐Tello(Dana-Farber Cancer Institute), Thaís S. Sabedot(Henry Ford Hospital), Paloma Cejas(Dana-Farber Cancer Institute), Norma I. Rodríguez-Malavé(Cedars-Sinai Medical Center), Ji-Heui Seo(Dana-Farber Cancer Institute), De‐Chen Lin(Cedars-Sinai Medical Center), Ursula A. Matulonis(Dana-Farber Cancer Institute), Beth Y. Karlan(Cedars-Sinai Medical Center), Simon A. Gayther(Cedars-Sinai Medical Center), Bogdan Paşaniuc(University of California, Los Angeles), Alexander Gusev(Dana-Farber Cancer Institute), Houtan Noushmehr(Henry Ford Hospital), Henry W. Long(Dana-Farber Cancer Institute), Matthew L. Freedman(Broad Institute), Ronny Drapkin(Penn Center for AIDS Research), Richard A. Young(Whitehead Institute for Biomedical Research), Brian J. Abraham(St. Jude Children's Research Hospital), Kate Lawrenson(Cedars-Sinai Medical Center)
Science Advances
November 24, 2021
Cited by 77Open Access
Full Text

Abstract

Critical developmental “master transcription factors” (MTFs) can be subverted during tumorigenesis to control oncogenic transcriptional programs. Current approaches to identifying MTFs rely on ChIP-seq data, which is unavailable for many cancers. We developed the CaCTS (Cancer Core Transcription factor Specificity) algorithm to prioritize candidate MTFs using pan-cancer RNA sequencing data. CaCTS identified candidate MTFs across 34 tumor types and 140 subtypes including predictions for cancer types/subtypes for which MTFs are unknown, including e.g. PAX8, SOX17, and MECOM as candidates in ovarian cancer (OvCa). In OvCa cells, consistent with known MTF properties, these factors are required for viability, lie proximal to superenhancers, co-occupy regulatory elements globally, co-bind loci encoding OvCa biomarkers, and are sensitive to pharmacologic inhibition of transcription. Our predictions of MTFs, especially for tumor types with limited understanding of transcriptional drivers, pave the way to therapeutic targeting of MTFs in a broad spectrum of cancers.


Related Papers

No related papers found

Powered by citation graph analysis